Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...Sep 13, 2024, 08:15 ET Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA...
Leading brokers name 3 ASX shares to buy today Oct 20, 2024 Why the CSL share price 'looks undervalued' Oct 17, 2024 CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy ...
Company Codes:Australia:CSL, OTC-PINK:CSLLY, OTC-BB:CSLLY, OTC-QX:CSLLY, OtherOTC:CSLLY Clinical researchPhase IIIBest Places to Work MORE ON THIS TOPIC Rare diseases Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by...
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348)...
The Montgomery Fund and Montgomery [Private] Fund own shares in CSL. This article was prepared 07 February with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade CSL you should seek financial ad...